Log in to search using one of your social media accounts:

 

Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88 L265P Mutation

The B-cell receptor signaling pathway is important in the lymphomagenesis of many lymphomas, including marginal zone lymphoma (MZL). Herein we describe a case of extranodal MZL refractory to multiple lines of therapy. The presence of an IgM paraprotein prompted further evaluation, and the patient was found to have an MYD88L265P mutation. Treatment with ibrutinib led to a dramatic response with prompt resolution of symptoms and significant improvement in measurable sites of disease. The excellent response to ibrutinib in our patient with MYD88L265P-mutated refractory MZL supports a biological rationale for its use.Case Rep Oncol 2017;10:813 –818
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Conclusion The present study shows that A. xylosoxidans infection may not be associated with pulmonary B-cell lymphoma in a Japanese case series. Large-scale international studies are needed to clarify the role of A. xylosoxidans in pulmonary lymphoma. PMID: 29151525 [PubMed - as supplied by publisher]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Authors: Hayashi N, Fujita A, Saikai T, Takabatake H, Sotoshiro M, Sekine K, Kawana A Abstract Anaplastic lymphoma kinase (ALK) rearrangement is most commonly observed in lung adenocarcinoma in a subset of lung cancer. Large-cell neuroendocrine carcinoma (LCNEC) harboring an ALK rearrangement is very rare. Based on the findings from a transbronchial lung biopsy, a 75-year-old non-smoking woman was diagnosed with LCNEC with multiple liver and bone metastases. After seven cycles of cytotoxic chemotherapy, her genotype testing demonstrated ALK rearrangement. Subsequently, she was administered alectinib and exhibited a...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Authors: Tanaka Y, Taima K, Tanaka H, Itoga M, Ishioka Y, Shiratori T, Tsuchiya J, Sakamoto H, Takanashi S, Tasaka S Abstract Sarcoidosis is an inflammatory granulomatous disease that is systemic, but bone involvement is uncommon. A 68-year-old man was referred to our hospital complaining of right shoulder pain with numbness. Computed tomography revealed systemic lymphadenopathy and multiple bone lesions. Because malignant lymphoma with a mass lesion protruding into the vertebral canal was considered, he underwent urgent radiotherapy. Thereafter, a needle biopsy of the left parasternal node was performed and showed...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses the affordability of cancer treatments at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. Th... Author: VJHemOnc Added: 11/21/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses novel conceptual treatment approaches at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. A n... Author: VJHemOnc Added: 11/21/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses the evolution of CAR T-cell therapy at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. CAR T... Author: VJHemOnc Added: 11/21/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses recent developments in BTK inhibitors at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. BTK... Author: VJHemOnc Added: 11/21/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Conditions:   Adult Diffuse Large Cell Lymphoma;   Recurrent;   Adult Refractory Diffuse Large B-Cell Lymphoma Interventions:   Biological: DPX-Survivac;   Biological: Pembrolizumab;   Drug: Cyclophosphamide 50mg Sponsors:   Sunnybrook Health Sciences Centre;   ImmunoVaccine Technologies, Inc.;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma Interventions:   Drug: pralatrexate;   Dietary Supplement: Vitamin B12 and folic acid Sponsor:   Mundipharma (China) Pharmaceutical Co. Ltd Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(UNC Lineberger Comprehensive Cancer Center) A grant from The Leukemia&Lymphoma Society will help fund clinical research led by UNC Lineberger's Barbara Savoldo, MD, PhD, into an investigational chimeric antigen receptor (CAR) T-cell treatment for acute lymphoblastic leukemia that would include a built-in 'safety switch.'
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer & Oncology | Lymphoma